GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is producing ...

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.

GSK PLC on Monday said it has agreed to acquire Boston, Massachusetts-based IDRx Inc in a deal that will add to its " ... Subscribe now to see this Premium News article from Alliance News ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...